259262-50-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 3-(3-pyridinyloxy)-, 1,1-dimethylethyl ester
• Synonyms: 3-(Pyridin-3-yloxy)-piperidine-1-carboxylic acid tert-butyl ester;3-(1-t-Butoxycarbonyl-3-piperidinyloxy)-pyridine
• CAS NO: 259262-50-5
• Molecular Formula: C15H22N2O3
• Molecular Weight: 278.34700
• Mol File: 259262-50-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 3-(3-pyridinyloxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 3-(3-pyridinyloxy)-, 1,1-dimethylethyl ester(259262-50-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 3-(3-pyridinyloxy)-, 1,1-dimethylethyl ester(259262-50-5)

Safety Data

• Hazardous Substances Data: 259262-50-5(Hazardous Substances Data)

Usage

Chemical class

Heterocyclic amine derivative

Use

Organic synthesis, pharmaceutical research

Function

Protecting group for amines in organic chemistry

Physical form

White to off-white crystalline powder

Molecular weight

267.36 g/mol

Versatility

Can be used in the synthesis of various pharmaceuticals and bioactive compounds due to its ability to protect functional groups and its stability under a wide range of reaction conditions.

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 224818-64-8 3-(3-Piperidinyloxy)-pyridine 

Relevant articles and documents

PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION

The present invention provides compounds of the formula:wherein m is 0, 1 or 2; p is 0 or 1; Y is O, S, S(O) or S(O)2 and R1 to R7 are various substituents as selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Al

Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis

In the past few years the focus on central acetylcholine receptors has shifted from-compounds with affinity for muscarinic acetylcholine receptors (mAChR) to compounds with affinity for nicotinic acetylcholine receptors (nAChR). The therapeutic potential